Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
Chaojie Zhu,Qing Wu,Tao Sheng,Jiaqi Shi,Xinyuan Shen,Jicheng Yu,Yang Du,Jie Sun,Tingxizi Liang,Kaixin He,Yuan Ding,Hongjun Li,Zhen Gu,Weilin Wang
DOI: https://doi.org/10.1016/j.bioactmat.2023.11.002
IF: 18.9
2023-11-28
Bioactive Materials
Abstract:Highlights • Basic information on solid tumor microenvironment and CAR-T therapy is provided. • The current dilemma in CAR-T for solid tumor treatment is summarized. • Rational design strategies of CAR-T therapy including CAR design, TME modulation, and delivery strategies are overviewed. • Combinatory adjuvant strategy for the patient-specific treatment of CAR-T therapy is introduced. Chimeric antigen receptor T cell denoted as CAR-T therapy has realized incredible therapeutic advancements for B cell malignancy treatment. However, its therapeutic validity has yet to be successfully achieved in solid tumors. Different from hematological cancers, solid tumors are characterized by dysregulated blood vessels, dense extracellular matrix, and filled with immunosuppressive signals, which together result in CAR-T cells' insufficient infiltration and rapid dysfunction. The insufficient recognition of tumor cells and tumor heterogeneity eventually causes cancer reoccurrences. In addition, CAR-T therapy also raises safety concerns, including potential cytokine release storm, on-target/off-tumor toxicities, and neuro-system side effects. Here we comprehensively review various targeting aspects, including CAR-T cell design, tumor modulation, and delivery strategy. We believe it is essential to rationally design a combinatory CAR-T therapy via constructing optimized CAR-T cells, directly manipulating tumor tissue microenvironments, and selecting the most suitable delivery strategy to achieve the optimal outcome in both safety and efficacy. Graphical abstract Download : Download high-res image (365KB) Download : Download full-size image
engineering, biomedical,materials science, biomaterials